May 2026 Research Update

This month added two real-world reminders about treatment response in cold agglutinin conditions: controlling hemolysis may require targeting the complement pathway in some people, and improvements in antibody blood tests do not always match what is happening in the bone marrow. The reports were not trials, but they show how cold agglutinin-related anemia can behave differently depending on the underlying cause. Together, they highlight that treatment effects can look very different when CAD is linked to a B-cell disorder versus when a new marrow disease is present. [1] [2]

In one person with cold agglutinin disease associated with a lymphoproliferative disorder (an underlying abnormal B-cell clone), B-cell directed drugs did not control ongoing red blood cell breakdown, but sutimlimab (a complement blocker) was followed by sustained resolution of hemolysis with blood count recovery over 12 months. The report connected this shift to molecular testing that supported a CAD-related lymphoproliferative disorder diagnosis, which helped explain why earlier approaches may not have matched the biology driving the hemolysis. This is a single-patient result, but it adds a concrete example of complement-targeted therapy lining up with the mechanism of disease. [1]

A different case report described a person with cold agglutinin syndrome who had a drop in cold agglutinin testing after rituximab, yet anemia worsened and evaluation later showed acute myeloid leukemia in the bone marrow. The report emphasized that blood test "serologic" improvement can be misleading if new or worsening low blood counts are being driven by a marrow problem rather than hemolysis alone. This case also illustrates that cold agglutinin-mediated hemolysis can rarely appear in the setting of leukemia, but the evidence here is limited to individual reports. [2]

For patients and caregivers, these case reports mainly add understanding rather than changing anything immediately, because they describe individual experiences and not head-to-head studies. They help clarify that "response" can mean different things: hemolysis control, overall anemia, and bone marrow health may not move together, and sometimes a different disease process can be uncovered when the course does not fit expectations. What remains uncertain is how often these situations occur and which people are most likely to follow these patterns, since the evidence is based on single cases. [1] [2]

This month brought practical clarity about getting the diagnosis and basic blood measurements right in cold agglutinin disease. One publication reinforced that the direct antiglobulin test (DAT) is central for identifying cold antibody-related hemolysis and separating it from other types. Another paper focused on a common lab problem in CAD: cold antibodies can clump red blood cells and distort routine red blood cell measurements, and the authors reported a method to reduce these errors. [3] [4]

The French guideline for autoimmune hemolytic anemia described how warm and cold forms are distinguished using DAT results and antibody features, and it specifically included CAD and cold agglutinin syndrome in its framework. It also summarized commonly used drug options for CAD, including rituximab with or without bendamustine, and noted sutimlimab as a newer option for CAD. As a guideline, it organizes existing knowledge rather than reporting new patient outcome data. [3]

The laboratory methods paper reported that warming cold-agglutinated blood to 37 C and measuring red blood cell values in a particular "closed-whole blood" analyzer mode could correct abnormal red blood cell parameters caused by clumping. In plain terms, the study focused on making routine numbers like red blood cell count and related indices closer to their true values when cold agglutinins interfere with the machine reading. The summary did not provide the number of patients tested, so it is hard to know how broadly this approach has been validated. [4]

For patients, this set of studies matters most for understanding why diagnosis and routine lab results can sometimes be confusing in CAD. The guideline reinforces that the DAT-based approach is a standard way to confirm the type of hemolytic anemia and frame next diagnostic steps, which can affect how results are interpreted over time. The lab-method paper is mainly early, practical research, but it helps clarify why red blood cell numbers can look "wrong" on automated tests and how laboratories may reduce that distortion; what remains uncertain is how widely the method works across different labs and devices. [3] [4]

This month included a rare example where cold agglutinin disease appeared alongside a broader autoimmune illness affecting multiple organs. The main message is that, in uncommon situations, cold agglutinin-related hemolysis can be one piece of a larger immune reaction rather than an isolated blood condition. Because this is a single case, it shows what can happen, not what usually happens. [5]

In the report, a person previously treated for Graves' disease with propylthiouracil developed c-ANCA vasculitis (an autoimmune inflammation of blood vessels) with cold agglutinin disease, along with kidney injury and pancreatitis. The patient improved after stopping the drug and receiving immune-suppressing treatment, plasmapheresis, and supportive care, with kidney function reported to improve toward baseline within 2 weeks. The case was presented as a delayed autoimmune reaction potentially linked to the earlier medication exposure. [5]

For patients and caregivers, this report mainly adds context for unusual, complex presentations rather than describing common CAD. It helps clarify that CAD can sometimes be seen together with other autoimmune problems and organ inflammation, which may change what doctors look for when symptoms extend beyond anemia or cold-related circulation issues. What remains uncertain is how often this happens and which risk factors matter, since the evidence comes from one patient and the mechanism is not proven. [5]